NASDAQ:KPTI - Karyopharm Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $23.60
Forecasted Upside: 166.97 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$8.84 As of 07/23/2021 01:00 AM ET

▼ -0.19 (-2.10%)

1 month | 3 months | 12 months

Get New Karyopharm Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for KPTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KPTI

^$23.60

▲ +166.97% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $23.60, with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 166.97% upside from the last price of $8.84.

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Karyopharm Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/27/2021	Robert W. Baird	Reiterated Rating	Buy		Low
5/4/2021	Robert W. Baird	Lower Price Target	Outperform	$35.00 ➝ $30.00	High
5/4/2021	Royal Bank of Canada	Lower Price Target	Outperform	$24.00 ➝ $19.00	High
5/3/2021	SVB Leerink	Lower Price Target	Outperform	$22.00 ➝ $15.00	High
4/11/2021	Royal Bank of Canada	Reiterated Rating	Buy	$24.00	Medium
2/12/2021	Barclays	Lower Price Target	Overweight	$26.00 ➝ $22.00	Low
2/11/2021	SVB Leerink	Lower Price Target	Outperform	$25.00 ➝ $22.00	Low
2/1/2021	Barclays	Lower Price Target	Positive ➝ Overweight	$31.00 ➝ $26.00	Low
1/12/2021	SVB Leerink	Lower Price Target	Outperform	$29.00 ➝ $25.00	High
11/3/2020	Morgan Stanley	Lower Price Target	Overweight	$34.00 ➝ $32.00	High
11/3/2020	SVB Leerink	Lower Price Target	Outperform	$30.00 ➝ $28.00	High
8/4/2020	SVB Leerink	Lower Price Target	Outperform	$31.00 ➝ $30.00	Medium
7/14/2020	Robert W. Baird	Set Price Target	Buy ➝ Outperform	$25.00 ➝ $35.00	Medium
7/14/2020	HC Wainwright	Reiterated Rating	Buy	$41.00	Medium
7/1/2020	Morgan Stanley	Initiated Coverage	Overweight	$34.00	Medium
6/23/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$31.00 ➝ $37.00	High
6/23/2020	Royal Bank of Canada	Boost Price Target	Outperform	$28.00 ➝ $30.00	High
6/23/2020	HC Wainwright	Boost Price Target	Buy	$40.00 ➝ $41.00	Medium
6/23/2020	Wedbush	Boost Price Target	Neutral	$18.99 ➝ $26.00	Medium
6/23/2020	Barclays	Reiterated Rating	Buy	$31.00	High
6/8/2020	Royal Bank of Canada	Reiterated Rating	Buy	$28.00	High
5/24/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	High
5/14/2020	HC Wainwright	Reiterated Rating	Buy		Medium
5/6/2020	Canaccord Genuity	Reiterated Rating	Buy		Medium
5/6/2020	HC Wainwright	Lower Price Target	Buy	$43.00 ➝ $40.00	High
5/5/2020	SVB Leerink	Lower Price Target	Outperform	$30.00 ➝ $29.00	High
4/13/2020	Royal Bank of Canada	Reiterated Rating	Buy	$34.00	High
4/7/2020	Wedbush	Reiterated Rating	Hold	$25.00	High
3/4/2020	Barclays	Initiated Coverage	Overweight	$30.00	High
3/3/2020	Canaccord Genuity	Reiterated Rating	Positive ➝ Buy	$22.00 ➝ $35.00	High
3/2/2020	Wedbush	Boost Price Target	Neutral ➝ Positive	$19.00 ➝ $25.00	High
3/2/2020	HC Wainwright	Boost Price Target	Positive ➝ Buy	$40.00 ➝ $43.00	High
3/2/2020	SVB Leerink	Boost Price Target	Outperform ➝ In-Line	$22.00 ➝ $30.00	High
1/17/2020	Wedbush	Downgrade	Outperform ➝ Neutral		High
1/14/2020	HC Wainwright	Reiterated Rating	Buy	$36.00 ➝ $37.00	Medium
1/9/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$23.00 ➝ $27.00	High
1/3/2020	Bank of America	Upgrade	Underperform ➝ Neutral		Medium
12/23/2019	HC Wainwright	Reiterated Rating	Buy	$36.00	N/A
12/12/2019	Canaccord Genuity	Reiterated Rating	Buy	$22.00	Low
11/6/2019	Wedbush	Boost Price Target		$15.00 ➝ $18.00	Low
11/5/2019	HC Wainwright	Boost Price Target	Buy	$32.00 ➝ $36.00	High
9/24/2019	Robert W. Baird	Set Price Target	Buy	$25.00	Low
9/17/2019	Wedbush	Boost Price Target	Outperform	$11.00 ➝ $15.00	Low
7/23/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$8.00 ➝ $16.00	High
7/8/2019	Wedbush	Boost Price Target		$6.00 ➝ $11.00	Low
7/5/2019	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $25.00	High
7/5/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $32.00	High
3/1/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$21.00 ➝ $7.00	Low
2/27/2019	HC Wainwright	Reiterated Rating	Buy		High
2/27/2019	Bank of America	Downgrade	Neutral ➝ Underperform	$15.00 ➝ $5.00	High
2/25/2019	Wedbush	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $14.00	Medium
1/3/2019	Bank of America	Upgrade	Underperform ➝ Neutral		High
12/3/2018	HC Wainwright	Reiterated Rating	Buy		High
11/30/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$23.00	Low
11/9/2018	Wedbush	Upgrade	Neutral ➝ Outperform	$19.00	Low
11/7/2018	HC Wainwright	Reiterated Rating	Buy	$30.00	Medium
8/29/2018	HC Wainwright	Reiterated Rating	Buy	$30.00	High
8/8/2018	Robert W. Baird	Reiterated Rating	Buy	$25.00	Medium
8/7/2018	Canaccord Genuity	Reiterated Rating	Buy	$27.00	Medium
6/15/2018	HC Wainwright	Reiterated Rating	Buy		Low
5/24/2018	Wedbush	Downgrade	Outperform ➝ Neutral	$20.00 ➝ $19.00	High
5/17/2018	HC Wainwright	Reiterated Rating	Buy	$30.00	Low
5/1/2018	SVB Leerink	Reiterated Rating	Outperform	$19.00 ➝ $24.00	High
4/30/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High
4/25/2018	Jefferies Financial Group	Reiterated Rating	Buy		Medium
4/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High
4/10/2018	Canaccord Genuity	Reiterated Rating	Buy	$22.00	Low
4/10/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$19.00 ➝ $20.00	High
4/2/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$19.00	High
3/21/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	Low
3/16/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$18.00 ➝ $19.00	Low
3/15/2018	Robert W. Baird	Set Price Target	Buy	$22.00	Medium
3/15/2018	HC Wainwright	Boost Price Target	Buy	$26.00	High
3/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High
3/12/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $22.00	Medium
3/2/2018	Royal Bank of Canada	Reiterated Rating	Buy	$22.00	High
1/25/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	High
12/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High
12/12/2017	HC Wainwright	Reiterated Rating	Buy	$23.00	High
11/15/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$23.00	N/A
11/3/2017	Royal Bank of Canada	Reiterated Rating	Buy	$15.00	N/A
11/3/2017	Robert W. Baird	Reiterated Rating	Buy		N/A
10/18/2017	Royal Bank of Canada	Reiterated Rating	Buy	$14.00	N/A
10/13/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A
10/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$18.00	N/A
9/20/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	High
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform	$14.00	High
8/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00 ➝ $19.00	Medium
8/8/2017	Canaccord Genuity	Set Price Target	Buy	$18.00	High
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	Low
7/4/2017	Robert W. Baird	Reiterated Rating	Outperform	$15.00	High
6/24/2017	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High
5/15/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$18.00	Low
4/7/2017	Jefferies Financial Group	Reiterated Rating	Buy	$17.00	High
4/6/2017	Robert W. Baird	Reiterated Rating	Outperform	$15.00	Low
4/5/2017	Wedbush	Reiterated Rating	Outperform	$14.00	Medium
3/17/2017	HC Wainwright	Reiterated Rating	Buy	$14.00	Medium
3/13/2017	Wedbush	Reiterated Rating	Outperform	$14.00	Low
3/13/2017	Canaccord Genuity	Reiterated Rating	Buy	$20.00	Low
3/13/2017	Jefferies Financial Group	Reiterated Rating	Buy	$14.00	High
3/7/2017	HC Wainwright	Reiterated Rating	Buy	$15.00 ➝ $14.00	N/A
3/4/2017	Wedbush	Reiterated Rating	Outperform	$14.00	N/A
3/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$14.00	N/A
12/7/2016	Wedbush	Reiterated Rating	Outperform	$14.00	N/A
12/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	$12.00 ➝ $14.00	N/A
11/8/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A
11/8/2016	HC Wainwright	Reiterated Rating	Buy		N/A
11/8/2016	Wedbush	Reiterated Rating	Outperform	$14.00	N/A
11/8/2016	Jefferies Financial Group	Reiterated Rating	Buy	$12.00	N/A
10/7/2016	SVB Leerink	Reiterated Rating	Outperform	$18.00	N/A
9/8/2016	Jefferies Financial Group	Reiterated Rating	Buy	$12.00	N/A
9/8/2016	HC Wainwright	Boost Price Target	Buy	$15.00 ➝ $16.00	N/A
9/6/2016	Robert W. Baird	Reiterated Rating	Positive	$16.00	N/A
8/30/2016	S&P Equity Research	Lower Price Target		$9.06 ➝ $7.55	N/A
8/30/2016	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$9.00 ➝ $12.00	N/A
8/18/2016	HC Wainwright	Initiated Coverage	Buy	$15.00	N/A
8/6/2016	Canaccord Genuity	Set Price Target	Buy	$20.00	N/A
8/4/2016	Wedbush	Reiterated Rating	Outperform	$14.00	N/A

(Data available from 7/25/2016 forward)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $8.84

$8.82

$9.08

50 Day Range

MA: $9.77

$8.84

$10.99

52 Week Range

Now: $8.84

$7.78

$18.50

Volume

486,187 shs

Average Volume

1,036,226 shs

Market Capitalization

$663.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Karyopharm Therapeutics?

The following sell-side analysts have issued research reports on Karyopharm Therapeutics in the last twelve months: Barclays PLC, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for KPTI.

What is the current price target for Karyopharm Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Karyopharm Therapeutics in the last year. Their average twelve-month price target is $23.60, suggesting a possible upside of 167.0%. Morgan Stanley has the highest price target set, predicting KPTI will reach $32.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $15.00 for Karyopharm Therapeutics in the next year.
View the latest price targets for KPTI.

What is the current consensus analyst rating for Karyopharm Therapeutics?

Karyopharm Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KPTI will outperform the market and that investors should add to their positions of Karyopharm Therapeutics.
View the latest ratings for KPTI.

What other companies compete with Karyopharm Therapeutics?

Other companies that are similar to Karyopharm Therapeutics include ATA, Sage Therapeutics, Prestige Consumer Healthcare, Pacira BioSciences, Insmed, OPKO Health, ALX Oncology, Verve Therapeutics, Corcept Therapeutics, Amicus Therapeutics, Arcus Biosciences, Prothena, Morphic, Nuvation Bio and Revance Therapeutics.

How do I contact Karyopharm Therapeutics' investor relations team?

Karyopharm Therapeutics' physical mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company's listed phone number is 617-658-0600 and its investor relations email address is [email protected] The official website for Karyopharm Therapeutics is www.karyopharm.com.